Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

BACKGROUND: Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed to prospectively compare the risk of early progression according to...

Descripción completa

Detalles Bibliográficos
Autores principales: Clatot, Florian, Perdrix, Anne, Beaussire, Ludivine, Lequesne, Justine, Lévy, Christelle, Emile, George, Bubenheim, Michael, Lacaille, Sigrid, Calbrix, Céline, Augusto, Laetitia, Guillemet, Cécile, Alexandru, Cristina, Fontanilles, Maxime, Sefrioui, David, Burel, Lucie, Guénot, Sabine, Richard, Doriane, Sarafan-Vasseur, Nasrin, Di Fiore, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254698/
https://www.ncbi.nlm.nih.gov/pubmed/32466779
http://dx.doi.org/10.1186/s13058-020-01290-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254698/
https://www.ncbi.nlm.nih.gov/pubmed/32466779
http://dx.doi.org/10.1186/s13058-020-01290-x

Ejemplares similares